<DOC>
	<DOC>NCT00683462</DOC>
	<brief_summary>A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping will be completed at screening and slow metabolisers will be excluded from participation in this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made during each treatment period. Safety and tolerability assessments will be a major component of the trial and all serious adverse events (SAE) will be immediately (within 24 hours) reported to both Targacept and to AstraZenca.</brief_summary>
	<brief_title>An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<criteria>Confirmed diagnosis of DSMIV ADHD Score of equal or more than 2 on at least six of nine items in at least one of the subscales of the ConnorÂ´s Adult ADHD Rating Scale (CAARSINV) Score of equal or more than 4 (at least moderate severity) on the Clinical Global ImpressionsSeverity (CGIS) test Current DSMIV Axis I psychiatric disorder (other than ADHD) Current user of cigarettes or other nicotinecontaining product. Slow metabolizers as indicated by CYP2D6 genotyping. Use of drugs affecting cognitive function within 8 weeks prior to enrollment visit or intended use during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>